JamesWilliamSmithyMD

PubMed

• A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease.
  Paul B Chapman, James W Smithy> ;Cancer Journal. 2024 Mar 25
• 2 citations
  Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
  Rami S Vanguri, James W Smithy, Yanyun Li, Mingqiang Zhuang, Colleen A Maher, Nathaniel Aleynick, Xiyu Peng, Hikmat Al-Ahmadie, Samuel A Funt, Jonathan E Rosenberg, Go...> ;The Journal of Pathology. 2023 Nov 1
• CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade.
  James W Smithy, Jason J Luke> ;Clinical Cancer Research. 2023 Jul 5
• 2 citations
  Adjuvant checkpoint blockade following complete local therapy for melanoma metastases.
  James W Smithy, Michael A Postow> ;Lancet. 2022 Oct 1
• 27 citations
  Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.
  James W. Smithy, Lauren M. Moore, Vasiliki Pelekanou, Jamaal Rehman, Patricia Gaule, Pok Fai Wong, Veronique Neumeister, Mario Sznol, Harriet M. Kluger, David L. Rimm> ;Journal for Immunotherapy of Cancer. 2017 Mar 21
• 3 citations
  Ensuring equity in the era of HLA-restricted cancer therapeutics.
  James W Smithy, Amanda Blouin, Lisa C Diamond, Michael Postow> ;Journal for Immunotherapy of Cancer. 2022 Nov 1
• 5 citations
  Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?
  James W Smithy, Alexander N Shoushtari> ;Cancer Discovery. 2022 Mar 1
• 10 citations
  Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events.
  James W Smithy, David M Faleck, Michael A Postow> ;Clinical Cancer Research. 2022 Apr 1
• 1 citations
  A Rapid Change in Pressure.
  Kristin D'Silva, Anand Vaidya, James W Smithy, William J Anderson, Barbara Cockrill> ;The New England Journal of Medicine. 2020 Jan 30
• 8 citations
  Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.
  Kimberly Loo, James W Smithy, Michael A Postow, Allison Betof Warner> ;Frontiers in Immunology. 2021 Jan 1
• 24 citations
  Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
  Michael A Postow, Debra A Goldman, Alexander N Shoushtari, Allison Betof Warner, Margaret K Callahan, Parisa Momtaz, James W Smithy, Ellesa Naito, Marina K Cugliari, V...> ;Journal of Clinical Oncology. 2022 Apr 1
• 11 citations
  Pancreas cancer: Therapeutic trials in metastatic disease
  James W. Smithy, Eileen M. O'Reilly> ;Journal of Surgical Oncology. 2021 May 1
• 6 citations
  Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
  James W. Smithy, Matthew J. Pianko, Colleen Maher, Michael A. Postow, Alexander N. Shoushtari, Parisa Momtaz, Paul B. Chapman, Jae H. Park, Margaret K. Callahan> ;Journal of Immunotherapy. 2021 Jan 1
• 86 citations
  Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center.
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;Circulation. Heart Failure. 2019 Oct 29
• 14 citations
  Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
  Swati Gupta, Leena McCann, Yvonne G. Y. Chan, Edwin W. Lai, Wei Wei, Pok Fai Wong, James W. Smithy, Jodi Weidler, Brian Rhees, Michael Bates, Harriet M. Kluger, David ...> ;Journal for Immunotherapy of Cancer. 2019 Sep 18
• 42 citations
  Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
  Pok Fai Wong, Wei Wei, Swati Gupta, James W. Smithy, Daniel Zelterman, Harriet M. Kluger, David L. Rimm> ;Journal for Immunotherapy of Cancer. 2019 Dec 1
• 101 citations
  High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.
  Maria I. Toki, Chris Merritt, Pok Fai Wong, James W. Smithy, Harriet M. Kluger, Konstantinos N. Syrigos, Giang T. Ong, Sarah Warren, Joseph M. Beechem, David L. Rimm> ;Clinical Cancer Research. 2019 Sep 15
• 79 citations
  Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma
  Pok Fai Wong, Wei Wei, James W. Smithy, Balazs Acs, Maria I. Toki, Kim Blenman, Daniel Zelterman, Harriet M. Kluger, David L. Rimm> ;Clinical Cancer Research. 2019 Apr 15
• 98 citations
  Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma
  Douglas B. Johnson, Jennifer Bordeaux, Ju Young Kim, Christine Vaupel, David L. Rimm, Thai H. Ho, Richard W. Joseph, Adil Daud, Robert M. Conry, Elizabeth M. Gaughan, ...> ;Clinical Cancer Research. 2018 Nov 1
• 74 citations
  Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
  Maria I. Toki, Nikita Mani, James W. Smithy, Yuting Liu, Mehmet Altan, Brad Wasserman, Rasikh Tuktamyshov, Kurt A. Schalper, Konstantinos N. Syrigos, David L. Rimm> ;Journal of Thoracic Oncology. 2018 Dec 1
• Postneoadjuvant adjuvant chemotherapy in resected N1 non-small cell lung cancer with residual nodal disease.
  James W. Smithy, Joshua E. Rosen, S. Gao, Anthony W. Kim> ;Journal of Surgical Oncology. 2017 Dec 1
• 163 citations
  A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
  Patricia Gaule, James W. Smithy, Maria I. Toki, Jamaal Rehman, Farah Patell-Socha, Delphine Cougot, Philippe Collin, Paul Morrill, Veronique Neumeister, David L. Rimm> ;JAMA Oncology. 2017 Feb 1
• 12 citations
  Publication of pivotal efficacy trials for novel therapeutic agents approved between 2005 and 2011: a cross-sectional study.
  James W. Smithy, Nicholas S. Downing, Joseph S. Ross> ;JAMA Internal Medicine. 2014 Sep 1
• Join now to see all

Lectures

• Changes in tumor mutational burden in serially biopsied non-small cell lung cancer. 
  2019 ASCO Annual Meeting - 6/1/2019